In the relentless pursuit of modern medicine, Targeted Protein Degradation (TPD) has emerged as a revolutionary therapeutic strategy, offering new hope for the treatment of numerous diseases. Traditional small-molecule inhibitors mainly actRead More…
Introduction Proteolysis-targeting chimeras (PROTEIN-TARGETING CHIMERASs) are a new class of small molecules that provide alternative ways to discover drugs by leading target proteins to be selectively destroyed. In contrast to conventional inhibitors thatRead More…
Nef is an accessory protein encoded by HIV-1, HIV-2, and other primate lentiviruses and is closely related to viral replication, persistent infection, and the development of AIDS. Nef interacts with a varietyRead More…
New lung cancer diagnoses and deaths have decreased as a result of reduced smoking and advances in early screening and treatment. However, lung cancer remains the leading cause of cancer deaths, accountingRead More…
Glioma is a primary intracranial malignant tumor originating from glial cells or progenitor cells, accounting for 25.5% of central nervous system tumors. Clinically, the treatment of glioma mainly depends on surgical resection,Read More…
Acute lymphoblastic leukemia (ALL) is a common disease. B-ALL and T-ALL account for 85% and 15% of the two lymphatic lineages of ALL, respectively, but patients with T-ALL have poor life qualityRead More…
Induced degradation of target proteins is a new concept in drug discovery. For eukaryotes, the ubiquitin-proteasome system is the main pathway of intracellular protein degradation, which participates in more than 80% ofRead More…
PROTAC (Proteolysis-Targeting Chimera) technology, by linking E3 ubiquitin ligase to the target protein, leads to the ubiquitin modification of the target protein, which is broken down into peptides and amino acids byRead More…
The wide range of application and the great potential in overcoming drug resistance and targeting non-proprietary targets, research and development in PROTAC field has been hot in recent years. PROTAC, protein degradationRead More…
Recently, Pfizer and Arvinas announced a partnership to develop and commercialize ARV-471, an oral PROTAC estrogen receptor protein degrader under development. Estrogen receptor (ER) is a well-known disease driver in most breastRead More…